Compare GSK plc (GSK) vs Medtronic PLC (MDT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs Medtronic PLC — how do they compare? GSK plc trades at $52.39 (market cap $101.34B), while Medtronic PLC trades at $83.98 (market cap $103.01B). The key difference: GSK plc and Medtronic PLC are close in size by market cap, and Medtronic PLC pays the higher dividend (3.58%). Which is the better fit depends on your goals.
| GSK | MDT | |
|---|---|---|
Market Cap | $101.34B | $103.01B |
Sector | Health | Health |
52-Week High | $61.18 | $105.35 |
52-Week Low | $36.20 | $73.75 |
Enterprise Value | $121.95B | $121.75B |
Dividend Yield | 3.49% | 3.58% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK's stock trades at $51.25, down 1.99% on the day, with a bearish technical signal from moving averages. Fundamentally, the company shows strong profitability with a 17.78% net margin and 36.42% ROE, supported by a consistent earnings beat history. Recent positive clinical trial results for Jemperli in rectal cancer and FDA approval for Utebzi highlight pipeline progress. Valuation appears reasonable with a P/E of 13.71 and EV/EBITDA of 9.16.
The outlook balances a solid core business and promising oncology pipeline against a mixed analyst consensus and near-term cash flow pressures. Key opportunities lie in execution of new drug launches and the upcoming CEO strategy update, while risks include clinical trial setbacks, competitive pressures, and integration of potential acquisitions like Nuvalent.
Medtronic (MDT) trades at $79.30, down 5.11% over 24 hours, with technical indicators showing bearish momentum. Fundamentally, the company reported strong earnings beats for three consecutive quarters and maintains solid profitability with a 13.2% net income margin. Recent news highlights the completion of the Scientia Vascular acquisition and bullish analyst coverage citing undervaluation and growth in cardiovascular and neuroscience segments.
The stock presents a compelling opportunity with a consensus price target of $97.50 representing 23% upside, supported by 58% analyst buy ratings. Key risks include increasing debt-to-asset ratios (31.11% in 2025) and margin pressures from tariffs and foreign exchange. The dividend aristocrat offers a near-decade high yield with consistent dividend growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About Medtronic PLC
One of the largest medical device companies, Medtronic develops and manufactures therapeutic medical devices for chronic diseases. Its portfolio includes pacemakers, defibrillators, heart valves, stents, insulin pumps, spinal fixation devices, neurovascular products, advanced energy, and surgical tools. The company markets its products to healthcare institutions and physicians in the United States and overseas. Foreign sales account for almost 50% of the company's total sales.
Read more on MDT →
